Five Prime Therapeutics, Inc.
(NASDAQ : FPRX)

( )
FPRX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
-0.29%80.010.9%$589.41m
CELGCelgene Corporation
-1.22%137.171.1%$556.07m
AMGNAmgen Inc.
0.05%186.281.1%$452.39m
BIIBBiogen Inc.
0.03%344.581.2%$391.35m
REGNRegeneron Pharmaceuticals, Inc.
-0.72%439.372.7%$313.54m
ALNYAlnylam Pharmaceuticals, Inc
-0.97%117.5510.7%$253.20m
VRTXVertex Pharmaceuticals Incorporated
-0.12%154.861.9%$219.44m
INCYIncyte Corporation
-0.43%115.142.5%$206.28m
ALXNAlexion Pharmaceuticals, Inc.
-2.04%140.241.9%$178.91m
ILMNIllumina, Inc.
-0.42%205.623.5%$138.87m
EXELExelixis, Inc.
-2.72%27.536.5%$135.05m
BLUEBluebird Bio, Inc.
-0.79%139.1017.3%$114.78m
BMRNBioMarin Pharmaceutical Inc.
-5.26%88.624.4%$108.97m
CLVSClovis Oncology, Inc.
-3.20%78.7216.5%$108.85m
SRPTSarepta Therapeutics, Inc.
-0.58%51.4216.9%$107.58m

Company Profile

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on discovering and developing novel protein therapeutics. The company advanced product candidates includes, FPA008, FPA144 and FP-1039/GSK3052230. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric (stomach) cancer. The FP-1039/GSK3052230 is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors. Five Prime Therapeutics was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, CA.